UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

线粒体肌病：治疗

Authors
Angela Genge, MD
Rami Massie, MD
Section Editor
Jeremy M Shefner, MD, PhD
Deputy Editor
John F Dashe, MD, PhD
Translators
王锁彬, 主任医师

引言

线粒体病是由线粒体呼吸链的病理性功能障碍引起，临床表现范围很广，且优先影响最依赖有氧代谢的器官系统。肌病可能是唯一的或主要的征象，或者仅仅是多系统疾病中的一个偶然发现。一般来说，神经系统受累(被称为线粒体脑肌病)较常见。当影响骨骼肌时，无论伴或不伴中枢神经系统受累，都称为线粒体肌病。

以下分类阐明了线粒体肌病的不同临床表现方式：

●表现为慢性进行性眼外肌麻痹(伴或不伴轻度近端肌无力)或Kearns-Sayre综合征

●表现为单纯性肌病，伴或不伴运动不耐受和/或肌痛

●表现为婴儿期和儿童期的严重肌病或脑肌病

                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: 2017-06 . | This topic last updated: 2016-08-31.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34:265.
  2. Chinnery PF. Mitochondrial disorders overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1224/ (Accessed on February 11, 2011).
  3. Kisler JE, Whittaker RG, McFarland R. Mitochondrial diseases in childhood: a clinical approach to investigation and management. Dev Med Child Neurol 2010; 52:422.
  4. Edmonds JL Jr. Surgical and anesthetic management of patients with mitochondrial dysfunction. Mitochondrion 2004; 4:543.
  5. Bau V, Zierz S. Update on chronic progressive external ophthalmoplegia. Strabismus 2005; 13:133.
  6. McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurol 2002; 1:343.
  7. Millhouse-Flourie TJ. Physical, occupational, respiratory, speech, equine and pet therapies for mitochondrial disease. Mitochondrion 2004; 4:549.
  8. Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006; 129:3402.
  9. Trenell MI, Sue CM, Kemp GJ, et al. Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy. Muscle Nerve 2006; 33:524.
  10. Taivassalo T, Shoubridge EA, Chen J, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001; 50:133.
  11. Cejudo P, Bautista J, Montemayor T, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. Muscle Nerve 2005; 32:342.
  12. Shoubridge EA, Johns T, Karpati G. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet 1997; 6:2239.
  13. Murphy JL, Blakely EL, Schaefer AM, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131:2832.
  14. Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; :CD004426.
  15. Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42:739.
  16. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37:212.
  17. Muller W, Reimers CD, Berninger T. Coenzyme Q10 in ophthalmoplegia plus - a double blind cross over therapeutic trial. J Neurol Sci 1990; 98 Suppl:442.
  18. Phase III trial of coenzyme Q10 in mitochondrial disease. http://clinicaltrials.gov/ct2/show/NCT00432744 (Accessed on May 16, 2012).
  19. Esposito LA, Melov S, Panov A, et al. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999; 96:4820.
  20. Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996; 47:583.
  21. Bakker HD, Scholte HR, Jeneson JA. Vitamin E in a mitochondrial myopathy with proliferating mitochondria. Lancet 1993; 342:175.
  22. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995; 242:472.
  23. Allen RJ, DiMauro S, Coulter DL, et al. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983; 13:679.
  24. Melegh B, Seress L, Bedekovics T, et al. Muscle carnitine acetyltransferase and carnitine deficiency in a case of mitochondrial encephalomyopathy. J Inherit Metab Dis 1999; 22:827.
  25. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20:1502.
  26. Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000; 55:1748.
  27. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35:235.
  28. Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003; 28:53.
  29. Artuch R, Vilaseca MA, Pineda M. Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis 1998; 21:837.
  30. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004; 62:1297.
  31. Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008; 5:558.
  32. De Stefano N, Matthews PM, Ford B, et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995; 45:1193.
  33. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66:324.
  34. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117:1519.
  35. Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003; 142:62.
  36. Artuch R, Salviati L, Jackson S, et al. Coenzyme Q10 deficiencies in neuromuscular diseases. Adv Exp Med Biol 2009; 652:117.
  37. Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 2012; 69:978.
  38. Sacconi S, Trevisson E, Salviati L, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010; 20:44.
  39. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57:515.
  40. Lalani SR, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005; 62:317.
  41. Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006; 66:253.
  42. Rötig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356:391.
  43. Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65:606.
  44. Auré K, Benoist JF, Ogier de Baulny H, et al. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 2004; 63:727.
  45. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358:2849.
  46. Filosto M, Scarpelli M, Tonin P, et al. Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 2012; 259:2699.
  47. Halter J, Schüpbach WM, Casali C, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 2011; 46:330.
  48. Bax BE, Bain MD, Scarpelli M, et al. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology 2013; 81:1269.
  49. Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 2002; 58:827.
  50. Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64:710.
  51. Adhya S, Mahato B, Jash S, et al. Mitochondrial gene therapy: The tortuous path from bench to bedside. Mitochondrion 2011; 11:839.
  52. Scarpelli M, Cotelli MS, Mancuso M, et al. Current options in the treatment of mitochondrial diseases. Recent Pat CNS Drug Discov 2010; 5:203.
  53. Tachibana M, Amato P, Sparman M, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493:627.
  54. Tachibana M, Sparman M, Mitalipov S. Chromosome transfer in mature oocytes. Nat Protoc 2010; 5:1138.
  55. Paull D, Emmanuele V, Weiss KA, et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013; 493:632.